All these findings in GC models suggest that devising HIF-1α inhibitors as a part of combination chemotherapy may have a high potential to circumvent resistance to chemotherapy-induced apoptosis and improve treatment response in GC. This evidence concerns the gene HIF1A and gastric cancer.